Theis Kipling

Corporate Officer/Principal at DEVYSER DIAGNOSTICS AB

Health Technology

Profile

Theis Kipling is currently the Chief Commercial Officer at Devyser Diagnostics AB since 2022.
Prior to this, he held the position of Chief Commercial Officer at Atlas Antibodies AB.

Theis Kipling active positions

Companies	Position	Start
DEVYSER DIAGNOSTICS AB	Corporate Officer/Principal	31/05/2022

All active positions of Theis Kipling

Former positions of Theis Kipling

Companies	Position	End
Atlas Antibodies AB Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden.	Corporate Officer/Principal	-

See the detail of Theis Kipling's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Theis Kipling's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
DEVYSER DIAGNOSTICS AB	Health Technology

Private companies	1
Atlas Antibodies AB Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden.	Health Technology